Published on

Clinical Toxicology — Sildenafil


1. Overview


Sildenafil is a selective phosphodiesterase type 5 (PDE5) inhibitor used to treat erectile dysfunction and pulmonary arterial hypertension.


Its therapeutic effect results from enhancement of nitric oxide–mediated cyclic guanosine monophosphate (cGMP) signaling, which relaxes vascular smooth muscle.


Most isolated sildenafil overdoses cause mild to moderate symptoms, including headache, flushing, dizziness, nasal congestion, and gastrointestinal discomfort.


Large ingestions may produce clinically important vasodilation, hypotension, reflex tachycardia, and occasionally severe complications.


The most dangerous drug interaction involves organic nitrates or nitrites, which can cause profound and potentially fatal hypotension when combined with sildenafil.


Other important adverse effects include prolonged erections, ischemic priapism, visual disturbances, and rare reports of sudden hearing or vision loss.


There is no specific antidote for sildenafil poisoning. Treatment is primarily supportive, with careful assessment of cardiovascular stability and interacting medications.


2. Forms and contemporary uses


Erectile dysfunction


Sildenafil is marketed as Viagra and in generic formulations.


Oral tablets commonly contain 25 mg, 50 mg, or 100 mg.


For most adults with erectile dysfunction, the usual starting dose is 50 mg approximately one hour before sexual activity.


The dose may be adjusted between 25 and 100 mg according to efficacy and tolerability.


The maximum recommended frequency is once daily.


Sildenafil facilitates erection in response to sexual stimulation; it does not independently produce an erection in the absence of sexual arousal.


Pulmonary arterial hypertension


Sildenafil is also marketed as Revatio and in other pulmonary hypertension formulations.


For adults with World Health Organization Group 1 pulmonary arterial hypertension, the recommended starting oral dose is generally 20 mg three times daily.


Higher prescribed doses may be used in selected patients according to current labeling and specialist assessment.


Pediatric pulmonary arterial hypertension


FDA-approved Revatio labeling includes use in children aged 1–17 years with pulmonary arterial hypertension.


Pediatric dosing depends on body weight and requires specialist management.


Available formulations


Pulmonary hypertension formulations include:


  • Oral tablets.
  • Oral suspension.
  • Intravenous injection.


The existence of different preparations is important when identifying an exposure or calculating the ingested dose.


Important prescribing distinction


Sildenafil prescribed for erectile dysfunction is typically taken as needed, while sildenafil for pulmonary arterial hypertension is administered on a regular schedule.


These regimens should not be interchanged without medical supervision.


3. Mechanism of action


Normal erectile physiology


During sexual stimulation, nitric oxide is released in penile erectile tissue.


Nitric oxide activates soluble guanylate cyclase, increasing intracellular cGMP.


cGMP promotes smooth muscle relaxation and increased blood flow into the corpus cavernosum.


Sildenafil activity


PDE5 normally breaks down cGMP.


Sildenafil inhibits PDE5, prolonging cGMP activity and enhancing smooth muscle relaxation.


Systemic vascular effects


PDE5 is also present in vascular smooth muscle outside the penis.


Its inhibition produces systemic vasodilation and reduces pulmonary vascular resistance.


This explains both sildenafil’s role in pulmonary arterial hypertension and its potential to cause hypotension.


Visual effects


Sildenafil also inhibits retinal phosphodiesterase type 6 (PDE6), although less strongly than PDE5.


PDE6 inhibition contributes to transient visual effects, including altered blue-green color discrimination and increased sensitivity to light.


4. Toxicokinetics


Absorption


Sildenafil is rapidly absorbed after oral administration.


Peak plasma concentrations generally occur approximately 30–120 minutes after dosing, with a median of around one hour in fasting individuals.


A high-fat meal can delay absorption.


Distribution


Sildenafil is extensively distributed into tissues.


Approximately 96% of circulating sildenafil and its principal metabolite are bound to plasma proteins.


Metabolism


Sildenafil undergoes extensive hepatic metabolism, predominantly through CYP3A4, with a smaller contribution from CYP2C9.


Its principal active metabolite is N-desmethylsildenafil.


This metabolite retains PDE5 inhibitory activity.


Elimination


Both sildenafil and its major active metabolite have terminal half-lives of approximately four hours in healthy adults.


Elimination occurs predominantly through metabolism and fecal excretion.


Clinical implications


Sildenafil exposure may be increased in patients with:


  • Advanced age.
  • Hepatic impairment.
  • Severe kidney impairment.
  • Concurrent use of strong CYP3A4 inhibitors.


In such patients, adverse effects may be more pronounced or prolonged.


5. Toxic dose


There is no validated dose that reliably separates mild from life-threatening poisoning.


Therapeutic doses


For erectile dysfunction, the usual maximum recommended single dose is 100 mg.


Higher doses increase the frequency and severity of adverse effects.


Volunteer overdose studies


Healthy volunteers have received single doses as high as 800 mg.


Adverse effects were generally similar to those seen at lower doses, but occurred more frequently and were more severe.


Important limitation


Tolerance of an 800 mg dose in selected healthy volunteers does not establish that 800 mg is safe after accidental or intentional overdose.


Patients with cardiovascular disease, interacting medications, impaired drug clearance, or significant coingestants may have more serious outcomes.


Pediatric exposures


Accidental ingestion can produce flushing, tachycardia, headache, and other symptoms in children.


The dose requiring medical assessment depends on age, formulation, and clinical circumstances.


No universal safe pediatric ingestion threshold should be assumed.


6. Clinical manifestations


Common adverse effects


Typical findings include:


  • Headache.
  • Facial flushing.
  • Dizziness.
  • Nasal congestion.
  • Dyspepsia.
  • Nausea.
  • Visual color changes.
  • Increased sensitivity to light.


Cardiovascular effects


Systemic vasodilation can cause a decrease in blood pressure.


Reflex tachycardia may occur.


Severe exposures may produce symptomatic hypotension, presyncope, syncope, and circulatory instability.


Neurologic effects


Headache and dizziness are common.


Marked confusion, seizures, or coma are not typical of uncomplicated isolated sildenafil poisoning.


Their presence should prompt investigation for hypotension-related complications, coingestants, or another diagnosis.


Gastrointestinal effects


Dyspepsia, nausea, vomiting, and abdominal discomfort may occur.


Musculoskeletal effects


Back pain and myalgia are possible, although they are generally more characteristic of certain other PDE5 inhibitors.


7. Serious cardiovascular complications


Severe hypotension


Sildenafil produces systemic vasodilation.


Severe hypotension is more likely when sildenafil is combined with:


  • Organic nitrates.
  • Organic nitrites.
  • Riociguat.
  • Certain alpha-adrenergic blockers.
  • Other blood-pressure-lowering medications.
  • Excessive alcohol intake.


Syncope and shock


Profound vasodilation can impair cerebral and coronary perfusion.


Patients may present with syncope, chest pain, marked weakness, or shock.


Myocardial infarction and sudden death


Myocardial infarction and sudden cardiac death have been reported in temporal association with sildenafil use.


However, a temporal association does not prove that sildenafil directly caused the event.


Many affected patients have underlying cardiovascular risk factors.


Sexual activity itself increases short-term cardiovascular demand.


Clinical implication


Chest pain, syncope, or hemodynamic instability after sildenafil use must be evaluated for acute coronary syndrome and other serious conditions.


Do not attribute chest pain automatically to an expected sildenafil adverse effect.


8. The nitrate interaction


This is the most important drug interaction in emergency care.


Mechanism


Organic nitrates increase nitric oxide signaling and cGMP production.


Sildenafil prevents normal cGMP breakdown.


Together, these effects can produce profound vasodilation and severe hypotension.


Contraindicated medications


Examples include:


  • Nitroglycerin.
  • Isosorbide dinitrate.
  • Isosorbide mononitrate.
  • Other organic nitrate medications.
  • Amyl nitrite and related recreational nitrites, often called poppers.


Recommended separation interval


The 2025 ACC/AHA acute coronary syndrome guideline advises avoiding nitrate administration for at least 24 hours after sildenafil or vardenafil.


For comparison, the recommended interval after tadalafil is at least 48 hours.


Important qualification


Twenty-four hours is not a guarantee of safety in every patient.


Sildenafil may persist longer when its metabolism is impaired by liver disease, interacting medications, or other factors.


After a major overdose, the interval at which nitrate treatment becomes safe is particularly uncertain.


Chest pain after sildenafil


Patients experiencing chest pain after sildenafil use should seek emergency medical care and immediately inform clinicians when sildenafil was taken.


Emergency teams should evaluate and treat possible acute coronary syndrome while avoiding nitrates during the relevant interaction period.


Alternative appropriate therapies and reperfusion strategies should not be delayed.


9. Riociguat and other interactions


Riociguat


Riociguat is a soluble guanylate cyclase stimulator used for selected forms of pulmonary hypertension.


It increases cGMP signaling.


Combining sildenafil with riociguat is contraindicated because of the risk of severe hypotension.


Alpha blockers


Alpha-adrenergic antagonists such as doxazosin and tamsulosin may increase the risk of postural hypotension when combined with sildenafil.


Patients should generally be stable on alpha-blocker therapy before sildenafil is initiated, with appropriate dose selection.


Strong CYP3A4 inhibitors


Ketoconazole, itraconazole, clarithromycin, and certain antiviral regimens can substantially increase sildenafil exposure.


The magnitude of interaction varies between medications.


Ritonavir


Ritonavir can markedly increase sildenafil concentrations.


For treatment of erectile dysfunction, prescribing information limits sildenafil to 25 mg within a 48-hour period when used with ritonavir.


Management differs when sildenafil is prescribed for pulmonary arterial hypertension; the entire regimen requires specialist review.


Other PDE5 inhibitors


Combining sildenafil with tadalafil, vardenafil, avanafil, or another sildenafil-containing preparation can increase adverse effects.


Such combinations are generally avoided unless specifically directed by a relevant specialist.


10. Visual complications


Transient color disturbances


Visual effects may include a blue tint, impaired blue-green discrimination, blurred vision, or photophobia.


These are usually reversible and dose-related.


Nonarteritic anterior ischemic optic neuropathy


Sudden vision loss associated with nonarteritic anterior ischemic optic neuropathy (NAION) has been reported after use of PDE5 inhibitors.


NAION can produce permanent visual impairment.


The relationship between sildenafil and NAION is difficult to establish conclusively because many affected patients also have vascular risk factors.


Nevertheless, the potential severity requires immediate assessment.


Clinical action


Sudden loss or significant reduction of vision in one or both eyes requires immediate discontinuation of sildenafil and urgent medical evaluation.


Such symptoms should not be attributed automatically to ordinary transient PDE6-related color changes.


Retinal disease


Patients with inherited retinal disorders such as retinitis pigmentosa require particular caution because some forms involve abnormalities of retinal phosphodiesterases.


11. Auditory complications


Sudden sensorineural hearing loss has been reported in temporal association with PDE5 inhibitors.


It may occur with:


  • Tinnitus.
  • Dizziness.
  • Vertigo.
  • Sudden unilateral or bilateral hearing loss.


A causal relationship has not been established in every case.


However, sudden hearing loss requires prompt cessation of the medication and urgent medical assessment.


Audiology or otolaryngology evaluation may be necessary.


12. Priapism


The historical statement that priapism had not been reported is obsolete.


Definition


Priapism is a prolonged erection that persists independently of sexual stimulation.


An erection lasting more than four hours requires immediate emergency assessment.


Risk factors


Predisposing conditions include:


  • Sickle cell disease.
  • Leukemia.
  • Multiple myeloma.
  • Previous priapism.
  • Certain penile anatomical abnormalities.
  • Use of other erectile dysfunction treatments.


Ischemic priapism


Ischemic priapism is a urologic emergency.


Prolonged lack of oxygen within the corpora cavernosa can cause tissue injury and permanent erectile dysfunction.


Treatment


Management should follow current urologic guidance.


For confirmed acute ischemic priapism, first-line treatment generally involves intracavernosal phenylephrine and corporal aspiration, with or without irrigation.


More invasive procedures may be required when these measures fail.


Important limitation


Oral medications, cold compresses, exercise, and observation must not delay definitive treatment of established ischemic priapism.


13. Pulmonary arterial hypertension considerations


Therapeutic benefit


Sildenafil can reduce pulmonary vascular resistance and improve clinical outcomes in selected patients with pulmonary arterial hypertension.


Pediatric use


FDA-approved Revatio labeling includes children aged 1–17 years.


Therefore, the older statement that sildenafil is not indicated in children is incorrect.


Pulmonary veno-occlusive disease


Patients with pulmonary veno-occlusive disease may develop pulmonary edema with pulmonary vasodilators.


Sildenafil is not recommended in this condition.


Sickle cell disease


Use of sildenafil for pulmonary hypertension associated with sickle cell disease has been associated with serious vaso-occlusive complications.


Treatment requires specialist assessment.


Overdose in patients with PAH


In patients receiving sildenafil for pulmonary hypertension, excessive doses or interruption of therapy may complicate an already serious cardiopulmonary condition.


Management must account for the underlying hemodynamics and concomitant PAH medications.


14. Diagnostic evaluation


Exposure history


Determine:


  • Exact product and dose.
  • Time and estimated amount ingested.
  • Indication for treatment.
  • Possible additional PDE5 inhibitors.
  • Nitrate, nitrite, or riociguat use.
  • Other antihypertensive medications.
  • Strong CYP3A4 inhibitors.
  • Underlying cardiac or pulmonary disease.


Ask specifically about erectile dysfunction products obtained online or from informal suppliers.


Initial examination


Assess blood pressure, heart rate, peripheral perfusion, mental status, and respiratory status.


Ask about visual changes, hearing loss, chest pain, and prolonged erection.


Laboratory investigations


For mild, isolated exposures, routine laboratory testing is often unnecessary.


In significant or symptomatic overdose, investigations may include:


  • Blood glucose.
  • Electrolytes.
  • Kidney function.
  • ECG.
  • Troponin when myocardial ischemia is suspected.
  • Blood gas and lactate in severe shock.


Coingestants


Acetaminophen and salicylate concentrations may be appropriate after deliberate or uncertain overdose.


Sildenafil concentrations


Serum sildenafil measurements are not routinely available or useful for acute management.


Treatment decisions should be based on clinical findings rather than serum concentration.


15. Differential diagnosis


Flushing and headache


Consider nitrate exposure, niacin, alcohol, calcium channel blockers, and scombroid fish poisoning.


Hypotension


Consider dehydration, antihypertensive overdose, nitrates, alpha blockers, sepsis, hemorrhage, and other causes of shock.


Visual disturbance


Other causes include migraine, retinal disease, optic neuritis, retinal vascular occlusion, methanol poisoning, and other toxic exposures.


Priapism


Consider hematologic disease, intracavernosal erectile dysfunction medications, penile trauma, and other medication-related causes.


Chest pain


Always assess for acute coronary syndrome or another cardiovascular emergency rather than assuming a benign drug effect.


16. Treatment of acute overdose


Initial priorities


There is no specific antidote.


Management consists of supportive care, assessment for interacting medications, and treatment of complications.


Mild poisoning


Patients with headache, flushing, nasal congestion, or mild dizziness usually improve with observation and symptomatic care.


Hypotension


Place the patient in a safe supine position.


Assess volume status and consider appropriately titrated intravenous isotonic crystalloid.


Avoid excessive fluids in patients with heart failure, pulmonary hypertension, or other conditions predisposing to fluid overload.


Persistent shock


For hypotension that does not respond adequately to initial measures, norepinephrine is a reasonable first-line vasopressor.


It should be titrated according to blood pressure, perfusion, and the underlying clinical condition.


Historical correction


The older recommendation to begin dopamine and add norepinephrine only if dopamine fails is not an appropriate contemporary default approach.


Chest pain


Evaluate according to current acute coronary syndrome guidance.


Do not administer nitrates during the clinically relevant period after sildenafil exposure.


Severe visual or auditory symptoms


Arrange urgent specialist evaluation.


Priapism


Arrange immediate urologic evaluation when an erection lasts more than four hours.


17. Gastrointestinal decontamination


Induced vomiting


Do not induce vomiting.


Gastric lavage


Routine gastric lavage is not recommended.


It has no established benefit in ordinary sildenafil poisoning and carries risks.


Activated charcoal


Activated charcoal is generally unnecessary after minor or uncomplicated sildenafil ingestion.


A single dose may be considered after an unusually large, clearly recent ingestion when the airway is protected and the expected benefit outweighs the risks.


There is limited direct evidence supporting improved clinical outcomes.


Multiple-dose charcoal


There is no established role for multiple-dose activated charcoal.


Whole-bowel irrigation


Whole-bowel irrigation is not recommended routinely.


18. Enhanced elimination


Hemodialysis


Hemodialysis is not expected to substantially increase sildenafil clearance.


Sildenafil is highly protein-bound, widely distributed, and minimally eliminated unchanged in urine.


Hemoperfusion


There is no established role for routine hemoperfusion.


Forced diuresis


Forced diuresis and urinary pH manipulation are not recommended.


Clinical implication


Severe poisoning requires effective supportive care rather than attempts at routine extracorporeal drug removal.


19. Pregnancy and lactation


Pregnancy


The former FDA pregnancy letter categories are obsolete.


Sildenafil is not indicated as a general treatment for pregnancy complications.


However, it may be used in selected pregnant patients with serious pulmonary arterial hypertension when specialist clinicians determine that the anticipated maternal benefit justifies treatment.


Fetal growth restriction


Trials of sildenafil for fetal growth restriction did not establish benefit, and one trial raised concerns about neonatal pulmonary hypertension.


Sildenafil should not be used routinely to treat fetal growth restriction.


Breastfeeding


Contemporary data indicate that sildenafil and its active metabolite are present in breast milk at low concentrations.


According to NIH LactMed, estimated infant exposure is far below therapeutic doses given to infants and is not expected to cause adverse effects.


The evidence remains limited, particularly for premature or medically vulnerable infants.


Important correction


The historical claim that the appearance of sildenafil in breast milk has not been studied is no longer accurate.


20. Observation and disposition


Minor isolated exposure


A patient with a clearly minor exposure and no symptoms may require only limited observation and poison-center advice.


Potentially significant ingestion


Patients with larger exposures require assessment of blood pressure, symptoms, interacting medications, and relevant underlying illnesses.


Observation duration


The historical recommendation of four to six hours may be reasonable for selected uncomplicated immediate-release ingestions.


However, it is not a validated universal observation period.


Longer monitoring may be needed after severe overdose, persistent hypotension, coingestion, strong CYP3A4 inhibition, or significant cardiovascular disease.


Hospital admission


Admission is appropriate for:


  • Persistent hypotension.
  • Syncope with concerning findings.
  • Chest pain or suspected ischemia.
  • Significant dysrhythmias.
  • Serious visual or hearing symptoms requiring continued assessment.
  • Priapism requiring emergency treatment.
  • Important coingestant toxicity.


Intensive care


ICU care may be necessary for refractory shock, serious cardiovascular complications, or respiratory failure.


Discharge


Discharge requires stable blood pressure and heart rate, resolution of clinically important symptoms, appropriate assessment of cardiac or other complications, and a safe follow-up plan.


Intentional ingestion requires an appropriate mental health assessment.


21. Expected course and prognosis


Most isolated sildenafil overdoses cause transient symptoms and resolve with supportive care.


Headache, flushing, dizziness, and mild hypotension generally improve as drug concentrations decline.


However, recovery may be slower when sildenafil clearance is reduced or interacting medications are present.


Severe nitrate-associated hypotension can be life-threatening.


Permanent complications are possible after ischemic priapism or certain serious visual or auditory events.


Although deaths have been reported in temporal association with sildenafil, individual cases often involve cardiovascular disease, other medications, or additional clinical factors.


22. Prevention and patient education


Patients should use sildenafil only according to the prescribed regimen.


Do not combine it with recreational nitrites or prescribed nitrates.


Tell healthcare professionals about recent sildenafil use before receiving treatment for chest pain.


Do not combine sildenafil with other erectile dysfunction drugs unless specifically directed by a clinician.


Seek urgent medical assessment for:


  • Chest pain or fainting.
  • Sudden loss of vision.
  • Sudden hearing loss.
  • Severe persistent dizziness.
  • An erection lasting longer than four hours.


Products marketed as herbal or natural sexual-performance enhancers may contain undeclared sildenafil or related medications.


Such products can create unrecognized drug interactions and expose consumers to unpredictable doses.


23. Clinical pitfalls


Treating sildenafil only as an erectile dysfunction drug. It also has approved pulmonary arterial hypertension indications in adults and children.


Assuming a tolerated 800 mg volunteer dose establishes safety. Individual overdose risk depends on underlying disease and drug interactions.


Overlooking nitrates or recreational nitrites. These combinations can cause profound hypotension.


Assuming nitrates are automatically safe exactly 24 hours after a major overdose. The guideline interval is a minimum under usual circumstances, not a guarantee in every patient.


Forgetting riociguat. Its combination with sildenafil is contraindicated.


Missing strong CYP3A4 inhibitors. These can markedly increase exposure.


Attributing chest pain to sildenafil alone. Acute coronary syndrome must still be evaluated.


Assuming all visual symptoms are harmless color changes. Sudden visual loss can indicate a serious ophthalmic emergency.


Ignoring sudden hearing loss. Urgent assessment is required.


Claiming priapism has not been reported. Prolonged erections can cause permanent injury.


Delaying treatment of ischemic priapism. An erection lasting more than four hours requires urgent medical evaluation.


Using dopamine as the routine first vasopressor. Norepinephrine is generally a more appropriate initial choice for refractory vasodilatory shock.


Performing routine gastric lavage or activated charcoal administration. Neither is established as standard management.


Using dialysis to remove sildenafil. Clinically meaningful enhanced elimination is not expected.


Assuming sildenafil is universally contraindicated in children or women. Its pulmonary hypertension indications and selected specialist uses require a different assessment.


Overlooking undeclared sildenafil in sexual-enhancement supplements. These products may cause unexpected exposure or drug interactions.


⸻


Key clinical conclusions


Sildenafil is a PDE5 inhibitor with important systemic vasodilatory effects.


Most isolated overdoses cause transient flushing, headache, dizziness, and gastrointestinal symptoms, but severe hypotension may occur, particularly with interacting medications.


The most dangerous interaction involves organic nitrates or nitrites. Riociguat is also contraindicated.


Sudden visual or hearing loss, suspected acute coronary syndrome, and priapism lasting more than four hours require urgent evaluation.


There is no specific antidote. Treatment is supportive, with fluid resuscitation when appropriate and vasopressor support for persistent shock.


Routine gastric lavage, activated charcoal, and hemodialysis have no established role in uncomplicated sildenafil overdose.


Contemporary clinical management must account for sildenafil’s distinct uses in erectile dysfunction and pulmonary arterial hypertension, including FDA-approved pediatric PAH treatment.

Image description
0 Comments